By VETTAPHARMA reporter – Derek Roche: Takeda’s Orzeyful (oveporexton) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with narcolepsy type 1 (NT1), also known as narcolepsy with cataplexy. The approval makes Orzeyful the first and only medicine indicated in Japan to address the disease beyond individual symptom management and marks the third regulatory approval worldwide for the medicine.
Orzeyful is a first-in-class oral orexin receptor 2 (OX2R) agonist designed to restore orexin signaling and address the underlying orexin deficiency associated with NT1. The medicine was discovered by Takeda scientists in Japan and is intended to address a broad range of daytime and nighttime symptoms associated with NT1, including excessive daytime sleepiness, cataplexy, and abnormal rapid eye movement sleep-related phenomena.
The Japanese approval is based on Takeda’s global Phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies. According to Takeda, the studies demonstrated statistically significant improvements across the full range of NT1 symptoms evaluated, including excessive daytime sleepiness, cataplexy, and other secondary measures. Orzeyful was generally well tolerated, with a safety profile consistent across clinical studies.
The most common adverse events reported with Orzeyful were insomnia, urinary urgency, urinary frequency, and excessive salivation. The Japanese product is available as 0.5 mg, 1 mg, and 2 mg tablets. The usual adult dose is 1 mg twice daily, with the first dose taken upon awakening and the second dose 3–5 hours later. The dose may be increased to 2 mg twice daily when tolerated and when sufficient efficacy is not observed.
NT1 is a chronic neurological disease caused by orexin deficiency. People living with NT1 can experience excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, sleep paralysis, hallucinations, and cognitive symptoms. The disease can affect work, education, and social interactions, while limited awareness and symptom complexity can contribute to an average diagnostic delay of more than 10 years.
The MHLW approval represents the third global regulatory approval for Orzeyful. The medicine is also approved in China for adolescents aged 16 years and older and adults with NT1 and in the United States for adults with NT1. Takeda said it is proceeding with launch preparations in Japan and expects to make Orzeyful available as quickly as possible.
Quick FAQs
1. What Is Orzeyful?
Orzeyful (oveporexton) is a first-in-class oral orexin receptor 2 agonist that selectively stimulates OX2R to restore orexin signaling and address the underlying orexin deficiency associated with narcolepsy type 1.
2. What Happened?
Japan’s MHLW approved Orzeyful for the treatment of adults with narcolepsy type 1, making it the third country to approve the medicine.
3. What Studies Supported The Approval?
The approval was based on the global Phase 3 FirstLight and RadiantLight studies, which evaluated Orzeyful in adults with narcolepsy type 1 and demonstrated statistically significant improvements across the range of NT1 symptoms assessed.
4. What Is Narcolepsy Type 1?
Narcolepsy type 1 is a chronic neurological disease associated with orexin deficiency and characterized by symptoms including excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, sleep paralysis, hallucinations, and cognitive symptoms.
5. What Were The Key Findings?
The Phase 3 studies demonstrated statistically significant improvements in excessive daytime sleepiness, cataplexy, and other secondary measures compared with placebo. Orzeyful was generally well tolerated across clinical studies.
6. Why Is This Important?
The Japanese approval expands access to the first-in-class orexin receptor 2 agonist and represents the third global regulatory approval for Orzeyful, providing a treatment designed to address the underlying orexin deficiency associated with narcolepsy type 1 rather than individual symptoms alone.
